Lv4
510 积分 2023-03-14 加入
PL04.13 Aumolertinib Maintenance after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer: Interim Results of the Phase III Study (POLESTAR)
3天前
求助中
EP08.02-003 Aumolertinib Plus Chemotherapy as 1st Line Treatment in Advanced Lung Cancer EGFR Mutation andctDNA Cleared Analysis
10天前
已完结
LBA61 Durvalumab (durva) after sequential chemoradiotherapy (CRT) in patients (pts) with unresectable stage III NSCLC: Final analysis from PACIFIC-6
11天前
已完结
Systemischer Effekt einer lokalen Strahlentherapie: erste klinische Evidenz
11天前
已关闭
Central nervous system efficacy of aumolertinib versus gefitinib in patients with untreated, EGFR‐mutated, advanced non‐small cell lung cancer: data from a randomized phase III trial (AENEAS)
11天前
已完结
Amivantamab plus lazertinib vs osimertinib in first-line EGFR-mutant advanced non-small cell lung cancer (NSCLC) with biomarkers of high-risk disease: A secondary analysis from the phase 3 MARIPOSA study
11天前
已关闭
Amivantamab plus Lazertinib in Previously Untreated EGFR -Mutated Advanced NSCLC
11天前
已完结
WS02.12 Aumolertinib Plus Anlotinib as 1st-Line Treatment for EGFR Mutant Non-Small Cell Lung Cancer: A Phase II Trial (ALWAYS)
11天前
已完结
Systemic treatment of brain metastases in non-small cell lung cancer
16天前
已完结
Systemic treatment of brain metastases in non-small cell lung cancer
17天前
已完结
皖公网安备34019202002308
